Table 2.
Specific treatment regiments for patients with advanced unresectable HCC.
| Treatment regiments | n=91 |
|---|---|
| TACE | |
| 0 | 13 (14.3%) |
| 1 | 44 (48.4%) |
| 2 | 15 (16.5%) |
| 3 | 10 (11.0%) |
| ≥4 | 9 (9.8%) |
| Lenvatinib dose (mg) | |
| 8 | 82 (90.1%) |
| 12 | 9 (9.9%) |
| Lenvatinib combined with PD-1 | |
| No | 44 (48.4%) |
| Yes | 47 (51.6%) |
| Lenvatinib combined with other therapies | |
| Lenvatinib | 8 (8.7%) |
| Lenvatinib + PD-1 | 2 (2.2%) |
| Lenvatinib + PD-1+ radiotherapy | 2 (2.2%) |
| Lenvatinib + TACE | 22 (24.2%) |
| Lenvatinib + TACE + PD-1 | 20 (22.0%) |
| Lenvatinib + TACE + PD-1 + radiotherapy | 14 (15.4%) |
| Lenvatinib + TACE + radiotherapy | 9 (9.9%) |
| Lenvatinib + TACE + radio frequency | 4 (4.4%) |
| Lenvatinib + TACE + PD-1+radio frequency | 6 (6.6%) |
| Lenvatinib + TACE + PD-1+radio frequency+radiotherapy | 1 (1.1%) |
| Lenvatinib + TACE + PD-1+radio frequency+radiotherapy+HAIC | 1 (1.1%) |
| Lenvatinib + TACE + radio frequency+radiotherapy | 1 (1.1%) |
| Lenvatinib + radiotherapy | 1 (1.1%) |
TACE, transcatheter arterial chemoembolization; PD-1, PD-1 antibody; HAIC, Hepatic artery infusion chemotherapy.